DUBLIN–(BUSINESS WIRE)–The “Cyber Security for Medical Devices Training Course (Mar 19th – Mar 20th, 2026)” training has been added to ResearchAndMarkets.com’s offering. The impact of Cyber Security incidents on society is high, and in critical infrastructures such as healthcare it impacts the ability for hospitals to provide care. Cybersecurity for medical devices is not just … [Read more…]

MINNEAPOLIS–(BUSINESS WIRE)–Coherent Solutions has released its 2026 Future of Fitness report, capturing years of domain knowledge from helping emerging and global fitness brands drive digital transformation, innovate, and improve member engagement. “The Future of Fitness: Winning with Digital Value Creation” takes lessons from real projects and fitness enthusiasts. The report comes as the Middle East … [Read more…]

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 9:45 a.m. Pacific Time. Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. A replay … [Read more…]

BOSTON–(BUSINESS WIRE)–Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that following evaluation of interim data from the RAMP 203 clinical trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) it will discontinue the trial to focus resources on clinical development of VS-7375, … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Pharmaceutical Regulatory Affairs in Asia Training Course (Mar 24th – Mar 26th, 2026)” training has been added to ResearchAndMarkets.com’s offering. The pharmaceutical market in Asia is growing at a rapid pace and presents both opportunities and challenges to those wishing to work in the region. Rather than a single market, Asia is a … [Read more…]

CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that OncoDaily has recognized Dr. Patrick Soon-Shiong as being one of “The 100 Most Influential People in Oncology in 2025.” Soon-Shiong is the company’s Founder, Executive Chairman and Global Chief Scientific and Medical Officer, and is a global thought leader in advancing … [Read more…]

DUBLIN–(BUSINESS WIRE)–“An Essential Overview of the Pharmaceutical and Biotech Industries Training Course (Mar 12, 2026)” has been added to ResearchAndMarkets.com’s offering. The pharmaceutical and biotechnology industries are both complex and developing at a rapid pace. This intensive one-day course will give you an invaluable overview, refresher and update on all the important aspects from discovery … [Read more…]

— Omeros to Host Conference Call Wednesday, January 7, 2026 at 4:30 p.m. ET — SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). To ensure broad … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Clinical Trial Agreements: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK Markets Training Course (Mar 18, 2026)” training has been added to ResearchAndMarkets.com’s offering. The life sciences sector is heavily regulated and CTAs are some of the most important agreements for companies operating in this sector. … [Read more…]

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that its board of directors has determined to effect a one-for-16 reverse stock split of Adicet’s common stock, par value $0.0001 per share. The reverse stock … [Read more…]